

# NYRx BLTG Program Update

---

## What Pharmacy Providers and Prescribers Need to Know

Effective **October 12, 2023**, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Kombiglyze® XR, Onglyza®, Renvela® powder pack, and Spiriva® HandiHaler®** will be **ADDED** to the program.
- **Firvanq® and Hetlioz® capsule** will be REMOVED from the program.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form and strength as the drug prescribed/ordered. This includes substituting the brand name drug when NYRx has determined it to be the less expensive alternative for the patient. Brand name drugs included in this program:

- Do not require "Dispense as Written" (DAW) or "Brand Medically Necessary" on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

## Important Billing Information

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of DAW Product Selection Code of "1"; Pharmacies should **submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive a NCPDP reject response of "22" which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this is DAW code "1" and "Brand Medically Necessary" on the prescription.

## NYRx BLTG Drugs

NYRx BLTG Program Brand Name Drugs*		
Advair Diskus®	Flovent® HFA	Rapamune® solution
Alphagan P® 0.15%	Glumetza®	<b>Renvela® powder pack</b>
Amitiza®	Kazano®	Renvela® tablet
Apriso®	Kitabis® Pak	Restasis®
Azopt™	<b>Kombiglyze® XR</b>	Retin-A® cream
Bethkis®	Lialda®	<b>Spiriva® HandiHaler®</b>
Cellcept® suspension	Nesina®	Symbicort®
Ciprodex®	Nexavar®	Tegretol® suspension
Combigan®	NuvaRing®	Tegretol® XR
Concerta®	<b>Onglyza®</b>	Trileptal® suspension
Copaxone® 20mg SQ	Oseni®	Vascepa®
Daytrana®	Pentasa®	Ventolin® HFA
Depakote® Sprinkle	Pradaxa®	Viibryd®
Dexilant®	Protonix® suspension	Zegerid® Rx
Epipen, Epipen JR	Pylera®	

\* This list is subject to change. For the most recent updates, see the [Brand Less than Generic Program Updates](#).

\* Drugs in this program may be subject to prior authorization requirements of other pharmacy programs.

## Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Pharmacy Program Preferred Drug List](#)
- [NYRx Education & Outreach Website](#)

## Contact Information

The NYRx Education and Outreach Call Center is available at 833-967-7310 from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

For NYRx program-related questions and non-member-specific questions, email the NYRx Education and Outreach team at [NYRxEO@magellanhealth.com](mailto:NYRxEO@magellanhealth.com).

The Education and Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.